A New Paradigm in Oncology and Hereditary Disease Therapeutics
The First A.I. Designed Mini-CARTM Therapeutics Targeting
Solid Tumors and Hereditary Disease
Solid Tumor Cancers
Hereditary Disease
CAR-Directed BioSpheres (Mini-CARTM) are innovative therapeutic agents that emulate the functions of T cells, Natural Killer cells, or macrophages. These miniaturized biospheres, derived from an allogeneic parent cell, house chimeric antigen receptors (CARs) and optional checkpoint inhibition tags. This unique design enables highly targeted and safe release of apoptotic proteins to diseased cells, offering a promising solution to the limitations of conventional CAR whole cell therapies in treating a variety of diseases, including solid tumor cancers and hereditary disease.
Advancing Precision Medicine to New Levels
Boundless Platform Applications Across Multiple Diseases and Diagnostics
CAR-Mediated BioSphere Therapeutic
Mini-CARTM
Introducing the mini-CAR Therapeutic: Advancing Precision Medicine
​
At Caravan Biologix, our focus is on leveraging the Mini-CAR technology to address critical human diseases. Our therapeutic platform provides a versatile foundation for developing nearly unlimited differentials of Mini-CAR that can be tailored to treat different human diseases, demonstrating our dedication to advancing healthcare on multiple fronts.
​
In addition to developing our own pipeline of Mini-CAR drugs, a key aspect of our strategy involves collaborating with other biotech companies, offering our platform for the development of their own Mini-CAR driven pipelines. The out licensing of our platform technology can result in the production of standalone therapies or co-therapeutics alongside their existing medicines, showcasing our commitment to advancing healthcare through strategic partnerships and collaborations.
​
In addition to licensing, we are actively utilizing the Mini-CAR platform to develop our own therapeutic pipeline, meticulously designed to enhance human health and showcase the platform's full range of druggable properties. This strategic approach ensures that our research not only benefits our own pipeline but also contributes to the broader understanding and utilization of the Mini-CARTM technology in the medical field.
​
Mini-CARs are innovative drug candidates designed to emulate the functions of immune cells. Our Mini-CAR pipeline is focused on precision targeting of specific diseases, with a particular emphasis on cancer therapy. We are exploring the potential of releasing perforins, granzymes, and p53 to solid tumor cancers, offering a more effective alternative to whole-cell-based treatments. Additionally, our approach involves restoring the immunomodulatory function of Natural Killer cells by targeting and releasing wild type granules, thereby preventing certain types of Hemophagocytic Lymphohistiocytosis (HLH). Furthermore, we are leveraging this technology to expanded clonal B-cell populations in systemic lupus erythematosus (SLE), addressing the underlying causes of this disease and aiming to improve patient outcomes.
Properties Beyond Whole Cell CAR Based Therapeutic Technologies
Allogenic
Multi-dosing Properties
Tumor-Honing
Migratory Tuning Capabilities
Ultra Low Cytotoxicity
Elimination of CRS
Superior Barrier Crossing
Organ Directed Treatment
Homogeneous and Low-Cost Manufacturing
Competitive Reproducibility
Mini-CAR
Enhanced Precision Immuno Therapy
Allogenic
Our Mini-CARs are derived
from allogenic and differentiated iPSCs
Biomarker
Targeting
We use advanced AI programming to select the best CARs based on Immunological Synapse quality
Tumor
Accessibility
The Mini-CAR is the optimal size to deeply penetrate solid tumors for maximum killing power
CRS
Prevention
With no genetic baggage or cytotoxic proteins, our Mini-CARs vastly reduce the occurrence of cytokine storm
Cytokine
Control
Our proprietary upstream cellular activation process allows for the expression of any desired therapeutic peptide or nucleic acid
Barrier
Crossing
Our Mini-CARs contain multiple properties that allow them to cross tissue barriers with unprecedented efficiency
Our Research Partners
Partnering
Contact Caravan Biologix to Build Your Mini-CAR Therapeutic Pipeline
Our robust partnering program can take your current therapeutic approach to new highly efficacious levels safer than other technologies.
​
